Neuroprotection against 6-OHDA toxicity in PC12 cells and mice through the Nrf2 pathway by a sesquiterpenoid from Tussilago farfara

Joohee Lee, Kwangho Song, Eugene Huh, Myung Sook Oh, Yeong Shik KimRedox 2018 · DOI

TL;DR

This study identifies a sesquiterpenoid from Tussilago farfara, named ECN, as a potent activator of the Nrf2 pathway. ECN demonstrates neuroprotective effects against oxidative stress in cell cultures and a mouse model of Parkinson's disease by upregulating the antioxidant enzyme heme oxygenase-1 (HO-1), suggesting its potential as a therapeutic agent for neurodegenerative diseases.

What Problem Does This Paper Address?

Neurodegenerative diseases like Alzheimer's and Parkinson's are characterized by progressive neuronal dysfunction and loss, with oxidative stress playing a significant role in their pathogenesis. The Nrf2 pathway is a critical regulator of the cellular antioxidant response, making it a promising therapeutic target for these conditions. However, identifying specific compounds that can effectively activate this pathway and translate to in vivo benefits remains an ongoing challenge. This paper addresses the need for novel neuroprotective agents by investigating the potential of a sesquiterpenoid, ECN, isolated from Tussilago farfara, to activate the Nrf2 pathway and protect against oxidative stress-induced neuronal damage.

Methods

The researchers employed a multi-faceted approach combining in vitro and in vivo methodologies:

  • Cell Viability Assays: Standard MTT assays were used to assess the protective effects of ECN against cytotoxicity induced by hydrogen peroxide (H₂O₂) and 6-hydroxydopamine (6-OHDA) in PC12 cells.
  • Western Blotting: This technique was used to quantify protein levels of key players in the Nrf2 pathway, including Nrf2, Keap1, and HO-1, in response to ECN treatment.
  • Quantitative Real-Time PCR (qRT-PCR): mRNA expression levels of Nrf2 and HO-1 were measured to assess transcriptional regulation.
  • ARE-Luciferase Assay: This assay was employed to evaluate the transcriptional activity of the antioxidant response element (ARE), a key DNA sequence bound by Nrf2.
  • siRNA Knockdown: Small interfering RNA (siRNA) was used to specifically reduce the expression of Nrf2, allowing researchers to confirm its essential role in ECN's effects.
  • ROS Measurement: The accumulation of reactive oxygen species (ROS) was measured using DCF-DA assay to investigate the role of oxidative stress in ECN's mechanism.
  • Pharmacological Inhibitors: Various inhibitors were used to probe the involvement of specific signaling pathways, including thiol reducing agents (NAC, DTT, Trolox) and kinase inhibitors (LY294002, U0126, SB203580, SP600125).
  • Animal Model: A 6-OHDA-induced mouse model of Parkinson's disease was utilized to assess ECN's in vivo efficacy.
  • Behavioral Tests: The rotarod test and apomorphine (APO)-induced rotation test were performed to evaluate motor function in the mouse model.
  • Immunohistochemistry: This technique was used to visualize and quantify dopaminergic neurons (using tyrosine hydroxylase (TH) and dopamine transporter (DAT) markers) in specific brain regions (striatum and substantia nigra) of the treated mice.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • ECN as a Novel Nrf2 Activator: The study firmly establishes ECN as a potent activator of the Nrf2 pathway, demonstrating its ability to upregulate both Nrf2 and its downstream target HO-1 at both the mRNA and protein levels.
  • Mechanism of Nrf2 Activation: Evidence suggests ECN may directly interact with Keap1, modifying critical cysteine thiols. This is a significant finding as it points to a direct mechanism of Nrf2 release and subsequent nuclear translocation, rather than solely relying on indirect oxidative stress induction. The failure of Trolox (a non-thiol antioxidant) to inhibit HO-1 induction, while thiol-reducing agents like NAC and DTT did, strongly supports this direct interaction hypothesis.
  • Akt Pathway Involvement: The study highlights the role of the Akt signaling pathway in ECN-induced Nrf2 activation, as inhibition of Akt with LY294002 abrogated Nrf2 nuclear translocation and ARE reporter gene activity.
  • In Vivo Efficacy: The successful translation of ECN's protective effects from cell culture to an animal model is a crucial insight. ECN ameliorated motor deficits and protected dopaminergic neurons in a 6-OHDA-induced Parkinson's disease model, underscoring its therapeutic potential.
  • Potential for BBB Penetration: The paper speculates on ECN's potential to cross the blood-brain barrier (BBB) based on its molecular weight and predicted partition coefficient, which is a critical factor for neuroprotective drugs.

Key Results

  • ECN protected PC12 cells from H₂O₂-induced cytotoxicity by up to 91.8% and from 6-OHDA-induced cytotoxicity by up to 87.9%.
  • ECN treatment significantly upregulated Nrf2 and HO-1 protein expression in a dose-dependent manner.
  • Nrf2 and HO-1 mRNA levels were increased by ECN, with a 3.3-fold and 5.2-fold increase, respectively, at 10 µM ECN.
  • Knockdown of Nrf2 using siRNA abolished ECN-induced HO-1 expression.
  • Pretreatment with thiol reducing agents (NAC, DTT) attenuated ECN-induced HO-1 expression and Nrf2 transcriptional activity, while Trolox did not.
  • ECN administration (5 mg/kg/day) in 6-OHDA-lesioned mice significantly improved motor performance in rotarod tests and reduced APO-induced rotations.
  • Immunohistochemical analysis showed that ECN treatment preserved TH-positive fibers and cells in the striatum and substantia nigra of 6-OHDA-lesioned mice.

Limitations and Future Work

  • Direct Keap1 Interaction Confirmation: While the study strongly suggests ECN directly interacts with Keap1 and modifies cysteine thiols, further studies are needed to pinpoint the exact cysteine residue(s) involved.
  • Blood-Brain Barrier (BBB) Permeation: Although ECN's physicochemical properties suggest potential BBB penetration, direct experimental validation of its ability to cross the BBB is necessary.
  • Mechanism of Akt Activation: The study identified Akt phosphorylation as upstream of Nrf2 activation, but the specific upstream kinases that activate Akt in response to ECN were not fully elucidated.
  • Broader Neurodegenerative Disease Models: While the study focused on a Parkinson's disease model, exploring ECN's efficacy in other neurodegenerative disease models (e.g., Alzheimer's) would be valuable.
  • Long-term Efficacy and Safety: Further research is needed to assess the long-term efficacy and safety profile of ECN in vivo.

Summary updated

Abstract

Oxidative stress plays a key role in neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. Therefore, the nuclear factor-E2-related factor 2 (Nrf2), a key regulator of the antioxidative response, is considered to be important as a therapeutic target for neurodegenerative diseases. We investigated the underlying mechanism of Nrf2-mediated neuroprotective effects against oxidative stress in the PC12 cell line by 7β-(3-ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranone (ECN), one of the sesquiterpenoids in Farfarae Flos. Pretreatment of PC12 cells with ECN had a protective effect against hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)- or 6-hydroxydopamine (6-OHDA)-induced cytotoxicity. ECN upregulated the ARE-luciferase activity and induced the mRNA expression of Nrf2 and antioxidant enzyme heme oxygenase-1 (HO-1). Knockdown of Nrf2 by small, interfering RNA (siRNA) abrogated the upregulation of HO-1, indicating that ECN had induced HO-1 via the Nrf2 pathway. Pretreatment with the thiol reducing agents, N-acetylcysteine (NAC) or dithiothreitol (DTT), attenuated Nrf2 activation and HO-1 expression. However, the non-thiol reducing antioxidant, Trolox, failed to inhibit HO-1 induction by ECN. These results suggest that ECN may directly interact with Kelch-like ECH-associated protein 1 (Keap1) and modify critical cysteine thiols present in the proteins responsible for Nrf2-mediated upregulation of HO-1. In a 6-OHDA-induced mouse model of PD, administration of ECN ameliorated motor impairments and dopaminergic neuronal damage. Taken together, ECN exerts neuroprotective effects by activating the Nrf2/HO-1 signaling pathway in both PC12 cells and mice. Thus, ECN, as an Nrf2 activator, could be an attractive therapeutic candidate for the neuroprotection or treatment of neurodegenerative diseases.
BibTeX
@inproceedings{lee2018neuroprotection,
  author = {Joohee Lee and Kwangho Song and Eugene Huh and Myung Sook Oh and Yeong Shik Kim},
  title = {{Neuroprotection against 6-OHDA toxicity in PC12 cells and mice through the Nrf2 pathway by a sesquiterpenoid from Tussilago farfara}},
  booktitle = {Redox},
  year = {2018},
  doi = {10.1016/j.redox.2018.05.015},
}
Figure